Skip to Content
Merck
  • The concurrent validity between leptin, BMI and skin folds during pregnancy and the year after.

The concurrent validity between leptin, BMI and skin folds during pregnancy and the year after.

Nutrition & diabetes (2013-09-11)
C L van der Wijden, H A Delemarre-van der Waal, W van Mechelen, M N M van Poppel
ABSTRACT

From a public health perspective it is important to know which of the currently used methods to estimate changes in maternal body fat during pregnancy and the year thereafter is the most adequate. To evaluate the concurrent validity between leptin and surrogates of fat measures: body mass index (BMI) and the sum of four skin folds. Data from the New Life(style) intervention study were analysed as a cohort study. Midwife practices in The Netherlands. Healthy pregnant nulliparous women. Anthropometric measurements were done and blood was collected at 15, 25 and 35 weeks of pregnancy and at 6, 26 and 52 weeks after delivery. Data were used if at least 4 out of the 6 measurements were available, leaving 87 women in the analyses. Spearman's correlation coefficients between leptin and BMI and between leptin and the sum of skin folds were calculated for each time point and for the changes between the time points. Correlations between leptin and BMI varied from 0.69 to 0.81. Correlations between leptin and the sum of skin folds were comparable, varying between 0.65 and 0.81.Correlations between changes in leptin and changes in BMI and the sum of skin folds, respectively, were much lower compared with cross-sectional correlations. Because of the high correlation among the three methods and because of the overlapping intervals, all methods seem to be equally adequate to estimate changes in maternal body fat during pregnancy and the year thereafter.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
mTOR phosphorylation Pathway Explorer Antibody MiniPack, This Antibody pack of Anti-mTOR antibodies contains Anti-phospho-mTOR Antibody(Ser2481), Anti-phospho-mTOR Antibody (Thr2446), Anti-phospho-mTOR (Ser2448).